Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer

被引:47
作者
Engelmark, M
Beskow, A
Magnusson, J
Erlich, H
Gyllensten, U [1 ]
机构
[1] Uppsala Univ, Rudbeck Lab, Med Genet Sect, Dept Genet & Pathol, S-75185 Uppsala, Sweden
[2] Roche Mol Syst, Berkeley, CA USA
关键词
D O I
10.1093/hmg/ddh201
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cervical cancer is a multifactorial disease and infection by oncogenic human papilloma viruses represents the main environmental risk factor. Only a subset of infections becomes persistent and develops into cancer, implying that genetic susceptibility factors are needed for malignant progression. Here, we use a population-based cohort of affected sib-pairs (ASPs) to examine the role of the human leukocyte antigen (HLA) class I and class II loci in cervical cancer susceptibility. Analysis of 278 ASPs revealed significant excess genetic sharing for all three HLA class II loci studied, DPB1, DQB1 and DRB1, with the strongest evidence for DQB1 and DRB1. No evidence of excess sharing was observed for the HLA class I HLA-B and HLA-A loci. When the material was stratified on the basis of the DQB1*0602/DRB1*1501 susceptibility haplotype, carriers showed significant sharing for all loci, whereas non-carriers showed no evidence of excess genetic sharing at any of the loci. However, for the DPB1 locus there was no difference in allele frequency. between carriers and non-carriers indicating that the effect seen in DPB1 is not simply due to linkage disequilibrium. Our results show that the HLA class II represents a major genetic susceptibility locus to cervical cancer in contrary to the class I that do not appear to have a significant impact on predisposition to the disease. The strongest class II effects are coming from the DQB1 and DRB1 loci, but the DPB1 locus also contributes to the susceptibility to cervical cancer.
引用
收藏
页码:1951 / 1958
页数:8
相关论文
共 67 条
[1]  
ABBAS A, 2000, CELLULAR MOL IMMUNOL, P82
[2]   Cancer in twins: Genetic and nongenetic familial risk factors [J].
Ahlbom, A ;
Lichtenstein, P ;
Malmstrom, H ;
Feychting, M ;
Hemminki, K ;
Pedersen, NL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (04) :287-293
[3]   The immigration dilemma: Avoiding the tragedy of the commons - Hardin,G [J].
Alexander, WM .
ECOLOGICAL ECONOMICS, 1996, 16 (02) :175-176
[4]   HLA DR-DQ ASSOCIATIONS WITH CERVICAL-CARCINOMA SHOW PAPILLOMAVIRUS-TYPE SPECIFICITY [J].
APPLE, RJ ;
ERLICH, HA ;
KLITZ, W ;
MANOS, MM ;
BECKER, TM ;
WHEELER, CM .
NATURE GENETICS, 1994, 6 (02) :157-162
[5]   Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions [J].
Arany, I ;
Tyring, SK .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (06) :453-460
[6]   Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri [J].
Beskow, AH ;
Gyllensten, UB .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (06) :526-531
[7]   HLA class II alleles associated with infection by HPV16 in cervical cancer in situ [J].
Beskow, AH ;
Josefsson, AM ;
Gyllensten, UB .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (06) :817-822
[8]   Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia [J].
Bontkes, HJ ;
de Gruijl, TD ;
Bijl, A ;
Verheijen, RHM ;
Meijer, CJLM ;
Scheper, RJ ;
Stern, PL ;
Burns, JE ;
Maitland, NJ ;
Walboomers, JMM .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :2453-2459
[9]   IMMUNOLOGICAL EVENTS IN REGRESSING GENITAL WARTS [J].
COLEMAN, N ;
BIRLEY, HDL ;
RENTON, AM ;
HANNA, NF ;
RYAIT, BK ;
BYRNE, M ;
TAYLORROBINSON, D ;
STANLEY, MA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 102 (06) :768-774
[10]   LOSS OF MHC CLASS-I EXPRESSION IN CERVICAL CARCINOMAS [J].
CONNOR, ME ;
STERN, PL .
INTERNATIONAL JOURNAL OF CANCER, 1990, 46 (06) :1029-1034